SCTB41 Plus SCTB39G With or Without Standard Therapy in Advanced Solid Tumors

NCT07665970 | Not Yet Recruiting Phase 1

• 1 other identifier: SCTB41-B39G-X201
• Study Type: interventional
• Target: 112
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB41 in combination with SCTB39G with or without standard therapy in adult patients with advanced malignant solid tumors. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.

Conditions

Advanced Malignant Solid Tumors

Outcome Measures

Primary Outcomes (2)

• Dose-Limiting Toxicity(DLT)

  Incidence of dose-limiting toxicities up to the Day 21 visit

  From Day 0 up to Day 21

• Objective Response Rate (ORR)

  The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1.

  Up to 2 years

Secondary Outcomes (4)

• Frequency of adverse events (AEs)

  Up to 2 years

• Disease Control Rate (DCR)

  Up to 2 years

• Progression-Free Survival (PFS)

  Up to 2 years

• Overall Survival (OS)

  Up to 2 years

Study Arms (1)

SCTB41+SCTB39G

EXPERIMENTAL

Drug: SCTB41+SCTB39G

Interventions

SCTB41+SCTB39G DRUG

SCTB41 plus SCTB39G of different doses, IV, every 3 weeks

SCTB41+SCTB39G

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Voluntarily sign the informed consent form (ICF);
• Male or female, ≥ 18 years and ≤ 75 years old;
• Survival duration more than 3 months;
• ECOG score ≤ 1 point;
• Histologically or cytologically confirmed diagnosis of advanced malignant solid tumor；
• At least one measurable tumor lesion according to RECIST v1.1;
• Adequate organ and bone marrow function.

You may not qualify if:

• Has participated in another clinical study within 4 weeks prior to the first dose;
• Has previously received other immunotherapies other than PD-(L)1 inhibitors；
• Other malignancies diagnosed within 5 years prior to the enrollment;
• Participants with brainstem, meningeal, spinal metastases, or compression; active central nervous system metastases;
• Significant bleeding risk;
• Presence of pleural effusion, peritoneal effusion, or ascites;
• Received chemotherapy, immunotherapy, biologic therapy, or other antitumor treatments within 4 weeks before enrollment；
• History of permanent discontinuation of immunotherapy due to immune-related toxicity or occurrence of ≥ Grade 3 irAEs;
• Presence of any active autoimmune disease or a history of autoimmune disease with an expected recurrence;
• History of severe allergies, severe drug allergies (including unapproved investigational drugs);
• History of organ transplantation or stem cell transplantation;
• Need for immunosuppressive drugs within 2 weeks prior to enrollment or anticipated during the study;
• Pregnant or breastfeeding female.

Sponsors & Collaborators

• Sinocelltech Ltd.: lead

Central Study Contacts

Zhe Huang

CONTACT

+86-10-58628288; zhe_huang@sinocelltech.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 18, 2026
• First Posted: June 24, 2026
• Study Start: June 30, 2026
• Primary Completion (Estimated): June 30, 2029
• Study Completion (Estimated): June 30, 2029
• Last Updated: June 26, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share